Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

Hitendra - Patel, Ronald Stoller, Miklos Auber, Douglas Potter, Chao Cai, William Zamboni, Gauri Kiefer, Khalid Matin, Amy Schmotzer, Ramesh K. Ramanathan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Rubitecan (RFS-2000, 9NC, Orathecin™) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-flurouracil based chemotherapy. Patients and results: Fourteen eligible patients were treated with rubitecan at 1.5 mg/m 2/day on a 5 day/week continuous schedule. Therapy was well tolerated with most adverse events in the mild to moderate category. Grade 3/4 toxicity consisting of anemia, diarrhea and elevated bilirubin was seen in 4 patients. No responses were seen in 13 evaluable patients. Overall median survival (95% confidence interval) was 10.1 (range 3.1-12.6) months, and median time to progression was 2.1 months. Conclusions: Administration of rubitecan was well tolerated, but this schedule does not appear to have clinical activity in patients with advanced previously treated CRC.

Original languageEnglish (US)
Pages (from-to)359-363
Number of pages5
JournalInvestigational New Drugs
Volume24
Issue number4
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Camptothecin
Fluorouracil
Colorectal Neoplasms
Drug Therapy
Appointments and Schedules
Bilirubin
Colonic Neoplasms
Anemia
Diarrhea
rubitecan
Confidence Intervals
Cell Line
Survival

Keywords

  • Colorectal cancer
  • Phase II
  • Rubitecan

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. / Patel, Hitendra -; Stoller, Ronald; Auber, Miklos; Potter, Douglas; Cai, Chao; Zamboni, William; Kiefer, Gauri; Matin, Khalid; Schmotzer, Amy; Ramanathan, Ramesh K.

In: Investigational New Drugs, Vol. 24, No. 4, 07.2006, p. 359-363.

Research output: Contribution to journalArticle

Patel, Hitendra - ; Stoller, Ronald ; Auber, Miklos ; Potter, Douglas ; Cai, Chao ; Zamboni, William ; Kiefer, Gauri ; Matin, Khalid ; Schmotzer, Amy ; Ramanathan, Ramesh K. / Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. In: Investigational New Drugs. 2006 ; Vol. 24, No. 4. pp. 359-363.
@article{adb22f3114924d639e5286c37ad09ae5,
title = "Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy",
abstract = "Background: Rubitecan (RFS-2000, 9NC, Orathecin™) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-flurouracil based chemotherapy. Patients and results: Fourteen eligible patients were treated with rubitecan at 1.5 mg/m 2/day on a 5 day/week continuous schedule. Therapy was well tolerated with most adverse events in the mild to moderate category. Grade 3/4 toxicity consisting of anemia, diarrhea and elevated bilirubin was seen in 4 patients. No responses were seen in 13 evaluable patients. Overall median survival (95{\%} confidence interval) was 10.1 (range 3.1-12.6) months, and median time to progression was 2.1 months. Conclusions: Administration of rubitecan was well tolerated, but this schedule does not appear to have clinical activity in patients with advanced previously treated CRC.",
keywords = "Colorectal cancer, Phase II, Rubitecan",
author = "Patel, {Hitendra -} and Ronald Stoller and Miklos Auber and Douglas Potter and Chao Cai and William Zamboni and Gauri Kiefer and Khalid Matin and Amy Schmotzer and Ramanathan, {Ramesh K.}",
year = "2006",
month = "7",
doi = "10.1007/s10637-006-6451-2",
language = "English (US)",
volume = "24",
pages = "359--363",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

AU - Patel, Hitendra -

AU - Stoller, Ronald

AU - Auber, Miklos

AU - Potter, Douglas

AU - Cai, Chao

AU - Zamboni, William

AU - Kiefer, Gauri

AU - Matin, Khalid

AU - Schmotzer, Amy

AU - Ramanathan, Ramesh K.

PY - 2006/7

Y1 - 2006/7

N2 - Background: Rubitecan (RFS-2000, 9NC, Orathecin™) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-flurouracil based chemotherapy. Patients and results: Fourteen eligible patients were treated with rubitecan at 1.5 mg/m 2/day on a 5 day/week continuous schedule. Therapy was well tolerated with most adverse events in the mild to moderate category. Grade 3/4 toxicity consisting of anemia, diarrhea and elevated bilirubin was seen in 4 patients. No responses were seen in 13 evaluable patients. Overall median survival (95% confidence interval) was 10.1 (range 3.1-12.6) months, and median time to progression was 2.1 months. Conclusions: Administration of rubitecan was well tolerated, but this schedule does not appear to have clinical activity in patients with advanced previously treated CRC.

AB - Background: Rubitecan (RFS-2000, 9NC, Orathecin™) is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-flurouracil based chemotherapy. Patients and results: Fourteen eligible patients were treated with rubitecan at 1.5 mg/m 2/day on a 5 day/week continuous schedule. Therapy was well tolerated with most adverse events in the mild to moderate category. Grade 3/4 toxicity consisting of anemia, diarrhea and elevated bilirubin was seen in 4 patients. No responses were seen in 13 evaluable patients. Overall median survival (95% confidence interval) was 10.1 (range 3.1-12.6) months, and median time to progression was 2.1 months. Conclusions: Administration of rubitecan was well tolerated, but this schedule does not appear to have clinical activity in patients with advanced previously treated CRC.

KW - Colorectal cancer

KW - Phase II

KW - Rubitecan

UR - http://www.scopus.com/inward/record.url?scp=33646500157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646500157&partnerID=8YFLogxK

U2 - 10.1007/s10637-006-6451-2

DO - 10.1007/s10637-006-6451-2

M3 - Article

C2 - 16525767

AN - SCOPUS:33646500157

VL - 24

SP - 359

EP - 363

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -